These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30307344)

  • 1. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study.
    Montes-Torres A; Aparicio G; Rivera R; Vilarrasa E; Marcellán M; Notario J; Soria C; Belinchón I; de la Cueva P; Ferrán M; Carrascosa JM; Gómez FJ; Salgado L; Velasco M; Descalzo MÁ; García-Doval I; Daudén E;
    J Dermatolog Treat; 2019 Aug; 30(5):461-465. PubMed ID: 30307344
    [No Abstract]   [Full Text] [Related]  

  • 2. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review.
    Bartos G; Cline A; Beroukhim K; Burrall BA; Feldman SR
    Dermatol Online J; 2018 Nov; 24(11):. PubMed ID: 30695971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
    Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
    Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
    Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
    Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
    J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study.
    Dommasch ED; Lee MP; Joyce CJ; Garry EM; Gagne JJ
    J Am Acad Dermatol; 2018 Dec; 79(6):1061-1068.e1. PubMed ID: 29981385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
    Küster D; Nast A; Gerdes S; Weberschock T; Wozel G; Gutknecht M; Schmitt J
    Arch Dermatol Res; 2016 May; 308(4):249-61. PubMed ID: 26961372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis.
    Yu Q; Tong Y; Cui L; Zhang L; Gong Y; Diao H; Gao F; Shi Y
    Int Immunopharmacol; 2019 Aug; 73():442-450. PubMed ID: 31154289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
    Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
    Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
    J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
    Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
    Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.
    Nakamura M; Abrouk M; Farahnik B; Zhu TH; Bhutani T
    Cutis; 2018 Jan; 101(1):38;42;56. PubMed ID: 29529104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.